AstraZeneca has launched in the UK a new pre-filled pen containing its once-weekly diabetes drug Bydureon (exenatide), offering patients a simpler route of administration. AstraZeneca has launched in ...
US regulators have given the thumbs-up to AstraZeneca's pre-filled, single-use pen injector version of its long-acting diabetes drug Bydureon. US regulators have given the thumbs-up to AstraZeneca’s ...
FDA approves the extended-release Bydureon Pen for the treatment of type 2 diabetes. FDA approved the Bydureon Pen (exenatide extended-release for injectable suspension) 2 mg as an adjunct to diet and ...
AstraZeneca is hoping new data showing its Bydureon diabetes drug cuts overall death risk could stave off competition from Novo Nordisk's potential next generation GLP-1 drug. Bydureon (exenatide), a ...
With a view to improve treatment for diabetes patients through innovative technology, product design and development firm Cambridge Consultants in association with AstraZeneca have developed Bydureon ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results